FDA Approves Novel Antipsychotic Cobenfy for Schizophrenia Treatment
The FDA has approved Cobenfy, a novel antipsychotic, for the treatment of schizophrenia. Explore the implications of this breakthrough medication, its safety profile, and how it may change the landscape of mental health treatment.